Tonix Pharmaceuticals' Live Virus Vaccine Candidate Shows Long-Term Protection From Mpox, Smallpox With 1 Dose, Animal Study Suggests
Portfolio Pulse from Vandana Singh
Tonix Pharmaceuticals' live virus vaccine candidate, TNX-801, shows long-term protection from mpox and smallpox with a single dose in animal studies. The company is advancing its development, and the vaccine has been selected by the NIH for Project NextGen. The stock saw a 4.01% increase, trading at $0.48.
August 16, 2024 | 5:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tonix Pharmaceuticals' TNX-801 vaccine shows promising results in providing long-term protection from mpox and smallpox with a single dose in animal studies. The stock saw a 4.01% increase, trading at $0.48.
The positive results from the animal studies and the stock's immediate price increase suggest a favorable short-term impact. The vaccine's potential to address public health emergencies and its selection by the NIH for Project NextGen further bolster investor confidence.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100